Literature DB >> 6304479

Monoclonal antibody specific for capsid antigen of Epstein-Barr virus.

K Takada, S Fujiwara, S Yano, T Osato.   

Abstract

A hybrid cell line (Cl-51) producing an anti-capsid antibody was obtained by fusion of mouse myeloma cells with spleen cells from mice immunized with purified P3HR-1 Epstein-Barr virus (EBV). Immunofluorescence showed that the Cl-51 antibody reacted with the cytoplasm and the nucleus of P3HR-1 and B95-8 cells, but not with Raji, BJAB, Molt-4, and superinfected Raji cells in the presence of cytosine arabinoside (Ara-C). The viable P3HR-1 and B95-8 cells were not stained nor was the viral infectivity neutralized. The Cl-51 antibody immunoprecipitated 123,000 and 120,000 dalton polypeptides of P3HR-1 and B95-8 cells, respectively, and both were sensitive to phosphonoacetic acid. Specific reactions were not evident with extracts of Raji cells and superinfected Raji cells in the presence of Ara-C. An analysis of the purified virus particles showed that this antibody recognized a capsid component of EBV.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6304479     DOI： 10.1007/bf02123496

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN： 0300-8584            Impact factor:   3.402


  24 in total

1.  Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma.

Authors:  J Menezes; W Leibold; G Klein; G Clements
Journal:  Biomedicine       Date:  1975-07

2.  Tumor initiators and promoters in the induction of Epstein-Barr virus.

Authors:  H zur Hausen; G W Bornkamm; R Schmidt; E Hecker
Journal:  Proc Natl Acad Sci U S A       Date:  1979-02       Impact factor: 11.205

3.  Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes.

Authors:  J Minowada; T Onuma; G E Moore
Journal:  J Natl Cancer Inst       Date:  1972-09       Impact factor: 13.506

4.  Immunofluorescence in cells derived from Burkitt's lymphoma.

Authors:  G Henle; W Henle
Journal:  J Bacteriol       Date:  1966-03       Impact factor: 3.490

5.  A film detection method for tritium-labelled proteins and nucleic acids in polyacrylamide gels.

Authors:  W M Bonner; R A Laskey
Journal:  Eur J Biochem       Date:  1974-07-01

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

7.  Search for tumor-specific immune reactions in Burkitt lymphoma patients by the membrane immunofluorescence reaction.

Authors:  G Klein; P Clifford; E Klein; J Stjernswärd
Journal:  Proc Natl Acad Sci U S A       Date:  1966-06       Impact factor: 11.205

8.  Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity.

Authors:  D A Thorley-Lawson; K Geilinger
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

9.  Monoclonal antibodies to Epstein-Barr virus-induced, transformation-associated cell surface antigens: binding patterns and effect upon virus-specific T-cell cytotoxicity.

Authors:  M Rowe; J E Hildreth; A B Rickinson; M A Epstein
Journal:  Int J Cancer       Date:  1982-04-15       Impact factor: 7.396

10.  Differential reactivity of human serums with early antigens induced by Epstein-Barr virus.

Authors:  W Henle; G Henle; B A Zajac; G Pearson; R Waubke; M Scriba
Journal:  Science       Date:  1970-07-10       Impact factor: 47.728
View more
  6 in total

1.  Gene mapping and expression of two immunodominant Epstein-Barr virus capsid proteins.

Authors:  W M van Grunsven; E C van Heerde; H J de Haard; W J Spaan; J M Middeldorp
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

2.  Clonal propagation of Epstein-Barr virus (EBV) recombinants in EBV-negative Akata cells.

Authors:  N Shimizu; H Yoshiyama; K Takada
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

3.  Characterization of a major protein with a molecular weight of 160,000 associated with the viral capsid of Epstein-Barr virus.

Authors:  B Vroman; J Luka; M Rodriguez; G R Pearson
Journal:  J Virol       Date:  1985-01       Impact factor: 5.103

4.  Qualitative and quantitative analyses of Epstein-Barr virus early antigen diffuse component by western blotting enzyme-linked immunosorbent assay with a monoclonal antibody.

Authors:  J C Lin; E I Choi; J S Pagano
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

5.  Two 21-kilodalton components of the Epstein-Barr virus capsid antigen complex and their relationship to ZEBRA-associated protein p21 (ZAP21).

Authors:  T R Serio; A Angeloni; J L Kolman; L Gradoville; R Sun; D A Katz; W Van Grunsven; J Middeldorp; G Miller
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

6.  CD21-mediated entry and stable infection by Epstein-Barr virus in canine and rat cells.

Authors:  L Yang; S Maruo; K Takada
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.